Trials / Enrolling By Invitation
Enrolling By InvitationNCT07073014
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia
- Status
- Enrolling By Invitation
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- BioMarin Pharmaceutical · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vosoritide | Open-label administration of vosoritide using weight-band dosing |
Timeline
- Start date
- 2025-06-20
- Primary completion
- 2040-12-01
- Completion
- 2040-12-01
- First posted
- 2025-07-18
- Last updated
- 2025-07-18
Locations
23 sites across 9 countries: United States, Australia, Canada, France, Germany, Italy, Japan, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07073014. Inclusion in this directory is not an endorsement.